Literature DB >> 32340583

COVID-19 pandemic: overview of protective-ventilation strategy in ARDS patients.

Julien Higny1, Frédéric Feye2, Frédéric Forêt3.   

Abstract

Objectives: In the context of COVID-19 pandemic, the aim of this manuscript is to provide a standard of care of patients with ARDS for non-emergency medicine trained physicians who are not customary with mechanical ventilation.
Methods: We conducted a systematic review of the literature to investigate the best practice recommendations regarding the mechanical ventilation of patients with ARDS.
Conclusion: We summarized the principal strategies for lung-protective ventilation of patients with ARDS. This focus is particularly addressed to physicians who are not experienced in the invasive respiratory management of ARDS patients. Nevertheless, it remains fundamental to acknowledge that new insights concerning this quickly spreading illness become available on a regular base.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; acute respiratory distress syndrome; mechanical ventilation; protective ventilation

Year:  2020        PMID: 32340583     DOI: 10.1080/17843286.2020.1761162

Source DB:  PubMed          Journal:  Acta Clin Belg        ISSN: 1784-3286            Impact factor:   1.264


  2 in total

1.  Pleural complications in patients with coronavirus disease 2019 (COVID-19): how to safely apply and follow-up with a chest tube during the pandemic?

Authors:  Kenan Can Ceylan; Guntug Batihan; Serkan Yazgan; Soner Gürsoy; Sami Cenk Kıraklı; Sena Ataman
Journal:  Eur J Cardiothorac Surg       Date:  2020-12-01       Impact factor: 4.191

2.  The Rapid Implementation of Ad Hoc Tele-Critical Care Respiratory Therapy (eRT) Service in the Wake of the COVID-19 Surge.

Authors:  Margarete Pierce; Steven W Gudowski; Karsten J Roberts; Anthony Jackominic; Karen K Zumstein; Amanda Shuttleworth; Joshua Ho; Phillip Susser; Alomi Parikh; John M Chandler; Ann Marie Huffenberger; Michael J Scott; C William Hanson; Krzysztof Laudanski
Journal:  J Clin Med       Date:  2022-01-29       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.